Better diagnosing heart transplant rejection and injury

April 10, 2018, University of Alberta Faculty of Medicine & Dentistry

The results of an international clinical trial for a new system of diagnosing heart transplant rejection and injury will be presented publicly for the first time at the International Society for Heart & Lung Transplantation (ISHLT) annual meeting, which will take place on April 11 and 12 in Nice, France.

Led by Dr. Phil Halloran and his team at the Alberta Transplant Applied Genomics Centre (ATAGC) at the University of Alberta, Edmonton, Canada, the INTERHEART study developed a molecular for reading transplant biopsies through the use of microarrays, commonly referred to as gene chips. The system promises greater accuracy in determining heart rejection and predicting future heart failure.

"Heart biopsies are conventionally read by microscopes, but there is extensive disagreement between doctors reading the biopsies, and therefore, errors," said Halloran, Muttart Research Chair in Clinical Immunology and a professor of medicine at the U of A. "The ATAGC team believes that biopsies should be read by their molecules, and has developed a 'molecular microscope' method to do just that."

The method uses gene chips—similar in some ways to computer chips—to interpret the molecules in biopsies. In the molecular microscope system developed by the ATAGC, software converts the chip readings into diagnoses automatically.

"Unlike conventional microscopes, the molecular assessment can also detect other serious injuries that are not rejection but can be confused with rejection," said Halloran. "The molecular microscope results suggest that unrecognized injury has been confused with rejection in many cases by conventional methods. This emerges as a major opportunity to improve care."

The molecular system diagnoses of two types: by T cells and by antibodies. Molecular microscope readings require less tissue and ATAGC research indicates that it is more precise and accurate than conventional methods.

The clinical trial was supported by an international team of co-investigators in North America, Europe and Australia. The next step is to use the readings to guide therapy for better outcomes. The molecular system is also being developed for , with the goal of changing care for those patients as well.

Explore further: Q&A: Life after a heart transplant

Related Stories

Q&A: Life after a heart transplant

March 28, 2018
Dear Mayo Clinic: My dad is 66 and was just put on the waitlist for a heart transplant due to coronary artery disease. How soon after the transplant would we know that he's out of the woods and his body didn't reject the ...

Revolutionary biopsy-reading invention reaches the masses

June 8, 2017
A groundbreaking University of Alberta invention that will impact transplant patients' outcomes—and possibly cancer outcomes in the future—is poised to become widely available now that the transplant test has been licensed ...

Lung transplant drug enters human testing in culmination of decades of work

March 26, 2018
In the culmination of decades of research at the University of Virginia Health System, doctors have begun human testing of a drug they hope will one day save many lives among lung transplant recipients.

Recommended for you

Compound improves stroke outcome by reducing lingering inflammation

April 20, 2018
An experimental compound appears to improve stroke outcome by reducing the destructive inflammation that can continue months after a stroke, scientists report.

Novel antioxidant makes old blood vessels seem young again

April 19, 2018
Older adults who take a novel antioxidant that specifically targets cellular powerhouses, or mitochondria, see age-related vascular changes reverse by the equivalent of 15 to 20 years within six weeks, according to new University ...

Changing how blood pressure is measured will save lives

April 19, 2018
Traditional methods of testing for high-blood pressure are no longer adequate and risk missing vital health signs, which can lead to premature death, a study co-led by UCL has found.

Study predicts 2018 flu vaccine will have 20 percent efficacy

April 19, 2018
A Rice University study predicts that this fall's flu vaccine—a new H3N2 formulation for the first time since 2015—will likely have the same reduced efficacy against the dominant circulating strain of influenza A as the ...

Eyes of adolescents could reveal risk of cardiovascular disease

April 19, 2018
New research has found that poorer well-being or 'health-related quality of life' (HRQoL) in adolescence could be an indicator of future cardiovascular disease risk.

Zika presents hot spots in brains of chicken embryos

April 19, 2018
Zika prefers certain "hot spots" in the brains of chicken embryos, offering insight into how brain development is affected by the virus.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.